Experimental Human Pneumococcal Carriage Augments IL-17A-dependent T-cell Defence of the Lung by Wright, Adam et al.
Experimental Human Pneumococcal Carriage Augments
IL-17A-dependent T-cell Defence of the Lung
Adam K. A. Wright1,2¤*, Mathieu Bangert1, Jenna F. Gritzfeld1, Daniela M. Ferreira1,
Kondwani C. Jambo1,3, Angela D. Wright4, Andrea M. Collins1,2, Stephen B. Gordon1*
1 Respiratory Infection Group, Liverpool School of Tropical Medicine, Liverpool, United Kingdom, 2National Institute for Health Research Biomedical Research Centre in
Microbial Diseases, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom, 3Malawi-Liverpool-Wellcome Trust Clinical Research
Programme, Chichiri, Blantyre, Malawi, 4Comprehensive Local Research Network, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom
Abstract
Pneumococcal carriage is both immunising and a pre-requisite for mucosal and systemic disease. Murine models of
pneumococcal colonisation show that IL-17A-secreting CD4+ T-cells (Th-17 cells) are essential for clearance of pneumococci
from the nasopharynx. Pneumococcal-responding IL-17A-secreting CD4+ T-cells have not been described in the adult
human lung and it is unknown whether they can be elicited by carriage and protect the lung from pneumococcal infection.
We investigated the direct effect of experimental human pneumococcal nasal carriage (EHPC) on the frequency and
phenotype of cognate CD4+ T-cells in broncho-alveolar lavage and blood using multi-parameter flow cytometry. We then
examined whether they could augment ex vivo alveolar macrophage killing of pneumococci using an in vitro assay. We
showed that human pneumococcal carriage leads to a 17.4-fold (p = 0.007) and 8-fold (p = 0.003) increase in the frequency
of cognate IL-17A+ CD4+ T-cells in BAL and blood, respectively. The phenotype with the largest proportion were TNF+/IL-
17A+ co-producing CD4+ memory T-cells (p,0.01); IFNc+ CD4+ memory T-cells were not significantly increased following
carriage. Pneumococci could stimulate large amounts of IL-17A protein from BAL cells in the absence of carriage but in the
presence of cognate CD4+ memory T-cells, IL-17A protein levels were increased by a further 50%. Further to this we then
show that alveolar macrophages, which express IL-17A receptors A and C, showed enhanced killing of opsonised
pneumococci when stimulated with rhIL-17A (p = 0.013). Killing negatively correlated with RC (r =20.9, p = 0.017) but not
RA expression. We conclude that human pneumococcal carriage can increase the proportion of lung IL-17A-secreting CD4+
memory T-cells that may enhance innate cellular immunity against pathogenic challenge. These pathways may be utilised
to enhance vaccine efficacy to protect the lung against pneumonia.
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Introduction
Nasopharyngeal colonisation with Streptococcus pneumoniae (the
pneumococcus) peaks in prevalence at 2–3 years of age [1] and
declines thereafter becoming 10% or less in adult-hood and
undetectable in the elderly [2]. Perturbations in host defence and/
or increased pneumococcal pathogenicity facilitate colonisation
and increase the frequency of progression to mucosal diseases such
as pneumonia [3]. Pneumonia is the leading cause of hospitalisa-
tion of children in the USA [4]. Elderly populations are also highly
susceptible to pneumonia [5]. Pneumococcal carriage is critical in
transmission and disease but paradoxically it is also essential for
the development of adaptive immunity.
Pneumococcal nasopharyngeal colonisation leads to the estab-
lishment of antigen specific memory CD4+ T-cells [6,7] and
specific antibody [8,9] at systemic and mucosal sites in mice. It is
well established in mice that, in concert with specific antibody and
innate immunity, pneumococcal-responding interleukin-17+ (IL-
17A+) and not interferon-gamma+ (IFNc+) CD4+ T-cells (Th-17
cells) are essential for protection against pneumococcal carriage
[6,7] but their role in the lung is less clear. Pneumococcal lung
infection in mice leads to the significant recruitment of CD4+ T-
cells into the lungs [3,7,10,11]. T cells are associated with
protection from pneumococcal pneumonia in some models [3] but
not others [8,12] possibly owing to variation in host genetic
background and the murine bacterial challenge model used.
In humans, increased rates of pneumococcal carriage in
children [13] and clinical cases of pneumonia in adults [14] were
associated with a reduction in circulating Th-1 (IFNc+) CD4+ T-
cells. Polymorphisms in the IL-17A gene are associated with
increased pneumococcal colonisation [15] and lung infection [16].
IL-17A and IFNc can be detected in pneumococcal stimulated
blood samples [17–19] and tonsillar mononuclear cells [20]. T
cells with a Th-1 [21] and Th-17 [22] phenotype have been
described in the human airway but their specificity for pneumo-
coccus has not been shown and it is unknown whether they are
directly elicited by pneumococcal carriage.
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Many functions are attributed to IL-17A secreted from Th-17
cells [23]. It can enhance neutrophil recruitment and phagocytosis
[18], increase antimicrobial peptide (beta defensin 2) production
[24], iBALT formation [25], and enhance polymeric Immuno-
globulin receptor expression on mucosal airway epithelial cells
[26]. Human Th-17 cells persist for longer and are more resistant
to apoptosis compared to Th-1 cells [27], making their increase an
attractive goal for vaccinations relying on cellular immunity.
Nasopharyngeal pneumococcal carriage mediated alterations in
the frequency and phenotype of pneumococcal-responding T-cell
response(s) in the lung that could impact vaccination strategies to
prevent acute lower respiratory tract infections or therapies
designed to augment/modulate lung immunity. We have devel-
oped an Experimental Human Pneumococcal Carriage (EHPC)
model to determine whether carriage could enhance cellular
immunity to pneumococcus in the lung. We showed that carriage
significantly increased lung and blood IL-17A+ CD4+ T-cell
responses. Furthermore, rhIL-17A, dependent upon IL-17 recep-
tor expression, can augment alveolar macrophage killing of
pneumococci, to increase innate mucosal defences of the lung.
Materials and Methods
Volunteer Recruitment and Experimental Human
Pneumococcal Carriage (EHPC) Model
Written informed consent was obtained from healthy adult
volunteers to participate in an approved study at the Royal
Liverpool and Broadgreen University Hospitals Trust. Approval
was obtained from Liverpool Central [REC 11/NW/0011] and
Sefton [08/H1001/52]) NHS Research Ethics Committees.
This work built on other EHPC development studies [28]. In
contrast to our previous pneumococcal challenge study design [28]
we omitted pre-challenge bronchoscopy with lavage from these
cohorts to increase our colonisation success rate. Pneumococcal
inoculation was done as published on-line [29]. Briefly, volunteers
(cohort details in Table 1) were challenged with a single intra-nasal
dose of either 23F (P833 strain a gift from Prof. JN Weiser,
University of Pennsylvania) or 6B (BHN418 strain a gift from Prof.
PW Hermans, University of Nijmegen) grown in vegitone broth
(Oxoid). The inoculation was performed while the volunteer was
seated comfortably in a semi-recumbent position. The head was
tilted back slightly and 100 ml of the bacterial inoculum was
dispensed, using a Gilson pipette (P100), across the nasal mucosa.
Serial dilutions of the inoculum were plated onto blood agar
(Oxoid) both before and after inoculation to confirm the dose
(Table 1).
Intra-nasal colonisation was assessed in nasal washes collected
48 hours, 7 and 14 days later. Sterile isotonic saline (5 mls) was
instilled into each naris with the subject seated at 45u to the
horizontal. Saline was held in the nasopharynx for 5 seconds,
following which the subjects were asked to tip their head gently
forward to allow the saline to run out of the nose and be collected
into specimen pots. Collected, pooled nasal washes were centri-
fuged at 3345 g for 10 minutes and the pellet was resuspended in
100 ml of Skim milk tryptone glucose glycerol (STGG) medium.
An aliquot (25 ml) was plated onto Columbia horse blood agar
(Oxoid) containing gentamicin (Sigma) and incubated at 37uC, 5%
CO2. After 24 hours plates were inspected for the presence of
draughtsman-like pneumococcal colonies. Isolated colonies were
subsequently sub-cultured to confirm pneumococcal phenotype
using Optochin sensitivity, bile solubility tests and for serotype
confirmation, latex agglutination kits (Statens Serum Institute)
were used. A further aliquot was used to perform a serial dilution
(Miles and Misra) and 3610 ml drops per dilution were dropped
onto blood agar for colony counting to determine the carriage
density (Table 1). Carriage density was calculated by obtaining the
average CFU per 100 ml (of STGG) and dividing this value by the
volume (ml) of nasal wash recovered to obtain CFU/ml of nasal
wash. Volunteers with a pneumococcal positive nasal wash that
was of the same serotype as the original inoculum were defined as
having established carriage. These volunteers were subsequently
selected for blood and BAL collection and subject data is
summarised in Table 1. We also recruited 9 age-matched healthy
adults (without pneumococcal colonisation) to act as controls and
obtained BAL and blood samples (Table 1 and presented in [28])
for comparison in a cross-sectional study.
PBMC and BAL Processing
PBMCs were processed by standard methods [28]. Briefly,
PBMCs were seeded in 48-well tissue culture plates in RPMI 1640
media with 2 mM L-glutamine (both Sigma-Aldrich) and 10%
human AB serum (complete media) lot 655272 (Invitrogen, UK),
prior to stimulation.
BAL was obtained and processed as previously described [28].
BAL cells were plated out into standard 24-well tissue culture
plates (Greiner, UK) to allow macrophages to adhere for 3 hours
at 37uC, 5% CO2. BAL cells were also allowed to adhere to 96-
well tissue culture plates (Greiner, UK) for an opsono-phagocytic
assay, described below. Non-adherent cells were collected from 24-
well tissue culture plates, washed and the pellet re-suspended in
1 ml of complete media in 48-well plates (Greiner, UK) and
incubated at 37uC, 5% CO2.
PBMC and BAL Stimulation
For Intracellular Cytokine Staining (ICS), PBMCs or BAL cells
(containing 1–26105 lymphocytes per well) were stimulated ex vivo
for 2 hours with influenza or one of the following pneumococcal
antigen preparations: 1.0 mg/ml heat-killed 6B cells (HK-6B),
13 mg/ml (of which 4.2 mg/ml is pneumococcal protein) 6B
culture supernatant (6B c/s), 13 mg/ml vegitone broth (‘vehicle’),
0.45 mg/ml of heat-inactivated influenza (Split Virion, Sanofi
Author Summary
Pneumococcal carriage is an important step in the
development of cellular and humoral pneumococcal
immunity but paradoxically may lead to mucosal diseases
such as pneumonia. The frequency of carriage and
pneumonia in young healthy adults is very low despite
frequent exposures suggesting the presence of appropri-
ate mucosal defences. Lung mucosal immunity against the
pneumococcus is poorly described in humans and lags
behind recent advances in our understanding of protective
cellular responses in mice. We have therefore developed a
method to experimentally induce pneumococcal carriage
in healthy adults in order to provide a mechanistic insight
into the protective responses elicited at the lung surface.
We were able to produce carriage in healthy adults and
show that – in the absence of respiratory symptoms or
local lung inflammation – pneumococcal-responding
(adaptive) cellular responses are increased to a large
extent. We also provide evidence of cellular cross-talk
between lung sentinels and the pneumococcal-respond-
ing adaptive response that may help prevent lung
infection in humans. Manipulation of this response may
provide novel therapeutic approaches to prevent pneu-
monia. Furthermore these tools allow better interpretation
of defective responses in at risk individuals such as the
elderly.
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Pasteur, 2010/11 strains) or left untreated (‘NS’) [28]. After
2 hours, 1 ml of Brefeldin A (BD biosciences) was added and cells
incubated for a further 16 hours before harvesting and staining for
the presence of intracellular cytokines.
An equal number of BAL cells were also seeded in parallel and
at an equal density to that described for ICS. These cells were
stimulated for 20 hours with HK-6B, or left untreated as described
above. Cells were harvested, pelleted and the supernatant removed
and kept at 280uC for cytokine/protein measurements. There
were no significant differences in the total number of cells,
macrophages (mean [6SD] 8.565.56105 vs 8.467.56105) or
lymphocytes (1.860.256105 vs 2.060.096105) per well between
non-colonised and colonised groups, respectively.
Flow Cytometry
Cells were harvested, stained and analysed as previously
described [28]. We gated on viable, CD3+CD4+CD45RO+ T-
cells (hereafter described as CD4+ memory T-cells) and identified
individual TNF, IL-17A and/or IFNc producing cells (or
combinations thereof) following stimulation (Figure S1 in the
online repository). Alveolar macrophage expression of IL-17RA
and RC was determined as described elsewhere [30].
Measurement of Secreted Proteins in Stimulated BAL Cell
Supernatant
BAL cell culture supernatants (not treated with Brefeldin A)
were analysed using a Th-1, Th-2, Th-17 Cytometric Bead Array
(CBA) kit (Becton Dickinson, UK). IL-22 and Beta-defensin 2
(BD2) were measured, in duplicate, using an anti-human IL-22
ELISA (R and D Systems, UK) or an anti-human BD2 ELISA
(Antigenix America Inc, USA), respectively. For the CBA, bead
populations were acquired on a BD LSR 2 and fcs files analysed
against the standard curve using FCAP version 1.0.1 (Soft Flow
Inc. USA). For ELISAs optical density was measured at 450 nm
using a Fluostar microplate reader (BMG Labtech, Germany) and
corrected for background at 540 nm (IL-22) or corrected using
empty wells (BD2). Standard curves were generated using linear
regression fit (IL-22) or 4-parameter fit logistic regression (CBA
and BD2) and had an r2 value greater than 0.97.
Opsonophagocytic Killing Assay (OPKA)
An OPKA using pneumococci and human alveolar macro-
phages was performed with minor modifications [31]. Briefly, D39
Pneumococci (serotype 2) were opsonised in a 1:16 dilution of
intravenous immunoglobulin (IVIG, Gamunex, Talecris, USA) in
Hanks and incubated at 37uC for 15 mins on a rotating platform.
Opsonised D39 (20 ml), complement (10 ml) and either 20 ml of
rhIL-17A (rhIL-17A, Biolegend 570502, reconstituted as described
below) or vehicle control (HBSS [with Ca2+ Mg2+] containing
10% AB serum [lot 655272]) were added to 16105 adhered
alveolar macrophages (multiplicity of infection of 1 pneumococcus
:100 cells) in 30 ml of RPMI+10% FCS to give a total reaction
volume of 80 ml in a 96-well flat bottom plate (Greiner, UK).
Following 2 hours incubation at 37uC, 10 ml of reaction mixture
was tilt plated, in triplicate, onto blood agar (Oxoid) and incubated
at 37uC, 5%CO2 overnight. Colony forming units (CFUs) from
cell supernatants were counted the following day.
Statistical Analysis
Data with a normal distribution (tested by Shapiro Wilks) were
compared with parametric tests. Data not following a normal
distribution were compared with non-parametric tests. OPKA
counts were assumed to follow a Poisson distribution. Changes in
CFUs over the three rhIL-17A doses were examined using Poisson
regression, with the corresponding vehicle counts included as
covariates and with adjustment for clustering within participants.
Flow cytometric data were analysed using FlowJo software version
7.6 (Treestar Oregon, USA). Graph and statistical analysis was
performed using GraphPad prism version 5.0 (California, USA).
Differences were considered significant if p#0.05.
Results
Experimental Human Pneumococcal Carriage Can Be
Achieved without Significant Side Effects
We recruited and inoculated 54 healthy young adult volunteers
in a dose ranging study, with serotype 6B pneumococcus in which
20 volunteers established carriage (37%). In a 23F dose ranging
cohort, 19 healthy adult volunteers were recruited and 2
established carriage (carriage positive 11%). In the 22 volunteers
in whom we established carriage, 17 reported no symptoms, 4
reported mild upper respiratory flu-like symptoms and 1 reported
abdominal pain and shortness of breath that resolved without
therapy.
From the cohort of 22 volunteers with experimentally induced
carriage, we were able to recruit 12 volunteers (average age 22.5
years) 36 days later (range 21–56 days) for BAL and blood
sampling (6B n=10; 23F n= 2, Table 1). These 12 carriage
positive volunteers had been challenged with a mean dose of
66,617645,637 CFUs (range 11,166–136,667 CFUs) per naris
(Table 1). The proportion CD4+ memory T-cells positive for TNF,
IL-17A or IFNc were measured in BAL and blood and compared
to controls without challenge (Table 1).
Lung (BAL) and Blood Responses to Pneumococcus and
Influenza in the Absence of Experimental Pneumococcal
Colonisation
BAL cells and PBMCs from carriage negative volunteers were
stimulated with pneumococcal antigens (HK-6B or 6B c/s) or
influenza and cytokine (TNF, IL-17A or IFNc) producing CD4+
memory T-cells were subsequently detected by ICS and flow
cytometry. Pneumococcal-responding CD4+ memory T-cells were
identified in BAL (Figure 1A and C and Figure S1 in the online
repository) and PBMCs (Figure S2 in the online repository) in the
absence of carriage. BAL CD4+ memory T-cells responding to
heat-killed pneumococci (HK-6B) in the absence of carriage were
TNF+ (0.2560.19% vs media control 0.160.07% p=0.02, paired
T-test) and IL-17A+ (0.1260.09% vs media control 0.0460.02%,
p= 0.01, paired T-test) but not IFNc+, consistent with a Th-17
phenotype (Figure 1A). There was a positive correlation between
TNF+ CD4+ memory T-cells and IL-17A+ CD4+ memory T-cells
(Pearson r = 0.8; p = 0.009) in response to HK-6B. Similar
observations were made when cells were stimulated ex vivo with
concentrated pneumococcal culture supernatant (6B c/s) and
compared to vegetone broth (vehicle) alone. We could detect
pneumococcal-responding IL-17A+ (0.1260.07 vs vehicle
0.0660.05 p= 0.004) but not TNF+ or IFNc+ CD4+ memory T-
cells, again consistent with a Th-17 phenotype. In contrast, CD4+
memory T-cells responding to influenza stimulation, in the
absence of carriage, were detectable in almost all BAL samples
(Figure 1B and Figure S1 in the online repository) and these cells
were TNF+ (0.3360.21% vs media control 0.160.06%, p= 0.006,
paired T-test) and IFNc+ (0.2760.22% vs media control
0.0760.05%, p= 0.03, paired T-test) CD4+ memory T-cells,
consistent with a Th-1 phenotype. IL-17A+ CD4+ memory T-cells
were not detected in response to influenza (Figure 1B).
EHPC and IL-17
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Human Pneumococcal Carriage Elicits a Higher
Frequency of IL-17A+ CD4+ Memory T-cells Compared to
Volunteers without Carriage
BAL responses. BAL differential cell counts from colonised
and non-colonised volunteers were similar (Table 2). BAL cells
collected from non-colonised and colonised groups and stimulated
ex vivo with influenza antigen, showed a similar percentage of
TNF+, IL-17A+ and IFNc+ CD4+ memory T-cells (Figure 2A and
Figure S2A and B in the online repository). In contrast, when BAL
cells were stimulated with HK-6B, IL-17A+ CD4+ memory T-cells
increased 17.4-fold in BAL following nasal carriage compared to
volunteers without carriage. Following carriage 1.5762.07% of
total CD4+ memory T-cells were IL-17A+ compared to
0.0960.08% without carriage (Figure 2A, p= 0.007). The IL-
17A signal was derived mainly from IL-17A+ CD4+ memory T-
cells that were also TNF+ (0.9761.24% vs non-colonised
0.0460.04%, p= 0.001) rather than single IL-17A+ cells
(0.2660.27% vs non-colonised 0.0360.03%, p= 0.014), Figure 3.
Stimulation of BAL cells from colonised volunteers with 6B c/s
elicited higher frequencies of TNF+, IL-17A+ and IFNc+ CD4+
memory T-cells but these responses were of borderline statistical
significance (Figure 2A). Carriage did elicit cells with a Th-1
Figure 1. Pneumococcal-responding IL-17A+ and TNF+ CD4+ memory T-cells are present in BAL from non-colonised volunteers. A
Heat-killed 6B pneumococci and B Influenza-antigen stimulated BAL cells from non-colonised volunteers (n = 9) were analysed for TNF, IL-17A and
IFNc expression using flow cytometry. TNF+, IL-17A+ or IFNc+ cells were measured and recorded as a percentage of total CD4+ memory T-cells in BAL.
C Representative flow cytometry dot-plots showing 6B stimulated CD4+ memory T-cells with the percentage of TNF+, IL-17A+ or IFNc+ positive cells
shown. * = p,0.05; ** = p,0.01 vs non-stimulated controls (media).
doi:10.1371/journal.ppat.1003274.g001
Table 2. Cellular profile of BAL collected from the
pneumococcal non-colonised and colonised groups.
Non-Colonised Colonised
Volunteers n=9 n=12
Volume returned (ml) 116622 122629
Total cells (6106/ml) 0.12960.1 0.0960.05
Macrophages (%) 93.463 93.764
Lymphocyte (%) 5.062 4.963
Neutrophil (%) 1.661.6 1.361.2
doi:10.1371/journal.ppat.1003274.t002
EHPC and IL-17
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phenotype (IFNc+CD4+ memory T-cells) in some volunteers but
overall these findings were inconsistent and thus we could not
demonstrate statistical significance. The proportion of IL-17A+
CD4+ memory T-cells in BAL did not correlate with the density of
carriage (shown in Table 1).
Blood responses. PBMCs from pneumococcal colonised
(n=10) and non-colonised (n=8) adults stimulated ex vivo with
influenza antigen elicited similar frequencies of TNF+, IL-17A+ and
IFNc+ CD4+ memory T-cells (Figure 2B). In contrast, HK-6B
stimulated PBMCs from colonised volunteers showed a significantly
greater percentage of IL-17A+ but not TNF+ or IFNc+ CD4+
memory T-cells, corresponding to an 8-fold increase, compared to
non-colonised volunteers (0.3260.3% vs non-colonised
0.0460.03%, p=0.003). PBMCs from colonised volunteers stimu-
lated with 6B c/s showed a greater percentage of IL-17A+ and IFNc+
(0.0860.07 vs non-colonised 0.0260.01, p=0.02) but not TNF+
CD4+ memory T-cells compared to non-colonised volunteers.
BAL Cells Stimulated with Pneumococci Elicit High Levels
of IL-17A but Not IFNc
To corroborate our flow cytometry findings we stimulated BAL
cells from colonised and non-colonised volunteers with HK-6B or
left them untreated and measured secreted IL-17A (Figure 4A),
TNF (Figure 4B), IL-2, IL-4, IL-6, IL-10, IL-22 and IFNc (all
Figure S4 in the online repository) by ELISA. Large quantities of
IL-17A were detected in the culture supernatant of HK-6B
stimulated BAL cells from non-colonised volunteers (stimulated
mean6SD 14,907610,843 vs non-stimulated 2,23363,298 pg/
ml, p = 0.06, Figure 4A). BAL cells from colonised volunteers and
stimulated with HK-6B elicited significantly greater quantities of
IL-17A protein compared to non-stimulated cultures (stimulated
22,393610,830 vs non-stimulated 2,00263,738 pg/ml, p = 0.03).
HK-6B stimulated BAL cells from colonised volunteers produced
50% more IL-17A protein than HK-6B stimulated BAL cells from
non-colonised volunteers but this difference was not statistically
significant. IL-17A production did not correlate with the
frequency of pneumococcal-responding IL-17A+ CD4+ T-cells in
BAL detected by flow cytometry (r = 0.13, p = 0.68). IL-17A
production did correlate with the number of alveolar macrophages
per well (r = 0.59, p = 0.03) indicative of an alternative source of
IL-17A, other than CD4+ memory T-cells, in BAL.
Comparisons between colonised and non-colonised groups,
following pneumococcal stimulation, revealed no significant differ-
ences with the exception of TNF (198.96476.8 vs non-colonised
5.863, p= 0.05 Mann-Whitney, Figure 4B). When corrected for
background (by subtracting data from non-stimulated cells) the
significance of this observation increased (TNF 195.76476.5 vs
non-colonised 2.6762.45, p= 0.026 Mann Whitney).
We then hypothesised that the presence of IL-17A (and TNF) in
stimulated culture supernatant would in turn elicit alveolar
macrophage secretion of constitutively expressed BD2 protein
Figure 2. Pneumococcal carriage increases the percentage of pneumococcal-responding IL-17A+ CD4+ memory T-cells in BAL and
blood. A BAL CD4+ memory T-cell and B Blood CD4+ memory T-cell responses from volunteers without (2, BAL n= 9, blood n= 8) or with (+, BAL
n= 11, blood n= 10) experimental pneumococcal carriage (indicated on x-axis). Cells were stimulated ex vivo with or without (not shown) influenza or
pneumococcal proteins as indicated. TNF+, IL-17A+ or IFNc+ responses shown are background subtracted and measured as % of total CD4+ memory
T-cells. Note the change in scale for the y-axis for each cytokine ns =not significant, * = p,0.05; ** = p,0.01 vs non-colonised volunteers.
doi:10.1371/journal.ppat.1003274.g002
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[32] after 20 hrs but this was below the limit of detection in all
samples (data not shown).
Human Alveolar Macrophages Express Functional IL-17A
Receptors and rhIL-17A Stimulation Increases Uptake of
Pneumococci
Human alveolar macrophages expressed both IL-17 RA
(743861646 mean channel units, n = 5) and RC (355162426
mean channel units n= 6) sub-units consistent with our previous
observations [30]. We thus used rhIL-17A and a modified OPKA
assay to mimic CD4 T cell action and our hypothesis was that
rhIL-17A could enhance the anti-pneumococcal response (inde-
pendent of serotype) of human alveolar macrophages. To calculate
a percentage increase or decrease compared to vehicle treated
cells, CFU averages from each rhIL-17A dose and respective
control were divided to obtain a ratio (Figure 5 and raw data in
Table 3). We showed a dose dependent increase in macrophage
Figure 3. Pneumococcal carriage increases the percentage of IL-17A+/TNF+ CD4+ memory T-cells in BAL. Sub-population analysis of 6B
stimulated BAL CD4+ memory T-cell responses from A non-colonised (n = 9) and B colonised volunteers (n = 11). The percentage of triple, double or
single CD4+ memory T-cells producing either TNF, IL-17A and/or IFNc (x-axis) are shown. Pneumococcal-responding double-producing (IL-17A+/TNF+)
CD4+ memory T-cells constitute the dominant phenotype following pneumococcal colonisation. Responses shown are background subtracted.
* = p,0.05; ** = p,0.01 vs non-colonised in A.
doi:10.1371/journal.ppat.1003274.g003
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uptake of pneumococci using 12.5 ng/ml, 125 ng/ml or 625 ng/
ml concentrations of rhIL-17A (Figure 5 and Table 3).
Macrophage uptake of pneumococci was increased 26% in the
presence of 125 ng/ml of rhIL-17A, compared to the 12.5 ng/ml
dose (12.5 ng/ml Control: 14.2 vs rhIL-17A stimulated 10.5 CFU
p=0.013). Increasing the rhIL-17A dose to 625 ng/ml further
increased pneumococcal uptake to 37% (12.5 ng/ml Control: 14.2
vs rhIL-17A stimulated 8.9 CFU p=0.004) (Figure 5 and Table 3).
We correlated the OPKA data described above with IL-17
receptor RA and RC mean fluorescence intensity on BAL alveolar
macrophages from a sub-set of the same volunteers (n = 6) to
determine whether this response was mediated by the IL-17
receptor. Our hypothesis was that increased mean receptor
expression positively correlates with increased percentage killing
compared to vehicle at the 125 ng/ml dose. There were no
significant correlations between OPKA data and expression of RA
Figure 4. BAL cells stimulated with pneumococci ex vivo elicit large quantities of IL-17A. BAL cells from non-colonised (open bars, n = 6) or
colonised (closed bars, n = 7, 1x 23F, 6x6B colonised) volunteers were stimulated with pneumococci (6B) or left untreated (NS) for 20 hours. Following
stimulation A IL-17A and B TNF were measured in pg/ml (mean6SD) in cell culture supernatant by ELISA. * = p,0.05.
doi:10.1371/journal.ppat.1003274.g004
Figure 5. rhIL-17A stimulated alveolar macrophages show increased killing of opsonised pneumococci. Human alveolar macrophages
from non-colonised volunteers were exposed to opsonised D39 pneumococci in the presence of rhIL-17A or a vehicle control (v/v). Percentage
changes in CFU following rhIL-17A (y-axis) treatment are shown as increase or decrease relative to vehicle, which was set at 0% for comparison (x-
axis). * = p,0.05, ** = p,0.01 vs 12.5 ng/ml of rhIL-17A.
doi:10.1371/journal.ppat.1003274.g005
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or combined expression of RA and RC. Contrary to our
hypothesis, however, mean expression of RC (355162426),
negatively correlated with killing (Spearman r=20.9, p = 0.017).
Discussion
We have shown that pneumococcal-responding IL-17A+ CD4+
memory T-cells are present at very low frequency in the healthy
adult lung in the absence of carriage. Further, using a novel
experimental human pneumococcal carriage (EHPC) model and
post carriage BAL collection an episode of pneumococcal carriage
resulted in a 17.4-fold increase and 8-fold increase in the
percentage of IL-17A+ CD4+ memory T-cells in BAL and blood,
respectively, compared to non-colonised volunteers. Using human
alveolar macrophages as effectors we showed that rhIL-17A
increased in vitro killing of S. pneumoniae in an opsonophagocytic
killing assay. These are the first data of which we are aware to
describe the relation of nasal carriage of a pathogenic organism
and lung IL-17A responses in humans and together support a role
for effector IL-17A+ CD4+ memory T-cell responses in the defence
of the lung against pneumococcal infection in adults.
The two major strengths of this study are that we have described
human CD4+ T-cell responses in the relevant mucosal site and
after a defined period of nasal colonisation. Other investigators
have identified and described pneumococcal-responding human
CD4+ T-cells in blood [13,19,20,33,34] and upper respiratory
tract mucosal tissue [13,20,35] but the initiation and duration of
carriage was unknown. The sharp increase in cellular response
seen immediately following an episode of carriage in this study,
and not seen in similar volunteers challenged with live bacteria but
without carriage [28], strongly supports a lung immunising role of
carriage in adults. Although a study of subjects at high risk of
pneumococcal disease (children, elderly) would be immunologi-
cally more relevant, it would clearly be ethically unacceptable in
the context of human pathogen challenge.
Our data contrast with decreases in antigen-specific responses
observed in blood in pneumococcal carriers in UK children [13]
or in endemic areas such as the Gambia [33] and in UK patients
with pneumonia [14], probably due to mucosal sequestration. Our
data concur, however, with increased IL-17A responses in other
studies [17] from an area with a high prevalence of pneumococcal
carriage and disease (i.e. Bangladesh) compared to Swedish
cohorts. The difference between our study and others may be
due to differences in the timing of sample collection relative to
exposure.
Human pneumococcal-responding IL-17A responses have been
demonstrated previously in peripheral blood [17,18,33] and in
adenoidal mono-nuclear cells [20,35] but in our study we have
examined the mucosal compartment where pneumonia becomes
established – the lung, which has not been examined before. In a
healthy adult population we showed, using flow cytometry, that
pneumococcal carriage elicits high frequencies of IL-17A+ and
TNF+ but not IFNc+ cells, within 5 weeks of colonisation. We have
used an extensive 7-colour panel that includes CD3+ and CD4+
antibodies that together with IL-17+ detection ensures that it is
highly likely that the responses we have identified in this
manuscript are derived from putative Th-17 cells rather than
innate sources. The IL-17A dominant responses in BAL and blood
contrast with studies that described higher IFNc and lower IL-17A
responses in blood [19,33] and tonsil [20] from healthy and HIV
affected [19] adults in Malawi and Gambia. There are multiple
factors, including the tissue site examined, burden of disease and
cellular plasticity [36] that may account for higher IFNc in these
studies and these differences between geographical areas of high
and low pneumococcal carriage warrant further attention. It is
likely, however, that both IL-17A and IFNc from T-cell effector
cells as well as T-regulatory cell populations play important but
different roles in protecting the lung against the pneumococcus
and pneunomococcal induced pathology [3,37–40]. Furthermore,
we identified increased IL-22 levels in some volunteers that were
independent of the IL-17 response suggesting a separate source of
IL-22 (possibly Th-22 cells), the diverse functions of which include
maintenance of epithelial integrity [41] and remodelling [42].
Murine models of airway inflammation have shown that IL-22 can
be pro-inflammatory (and thus pathological) in the presence of IL-
17A but in the absence of IL-17A can be anti-inflammatory/tissue
protective [43]. Determining the correct ‘‘balance’’ of Th-17, 22
and T-regulatory cells elicited following vaccination may be
important for generating adaptive anti-pneumococcal responses
that promote resolution and clearance and reduce immunopa-
thology.
We have also measured the cytokine response from lung cells
stimulated ex vivo with pneumococcus and shown that pneumo-
coccal stimulated BAL cells (from non-colonised and colonised
volunteers) produce IL-17A in quantities far greater than
described in other studies using blood [17–19] or lymphoid tissue
[20,35]. The response from colonised volunteers was 50% greater
compared to the non-colonised group who also had high levels of
IL-17A following stimulation that is likely to be derived from non-
Th-17 sources. This difference may be of relevance in vivo,
however, since TNF [44], which we have shown to be significantly
different between colonised and non-colonised groups using flow
cytometry (Figure 2A) and ELISA (Figure 4B), and IL-22 [45] can
both synergise with IL-17A to enhance epithelial derived CXC
chemokine production, important for the recruitment and
activation of neutrophils to the airway. It has been shown that
murine [46] and human [47] alveolar macrophages can also
produce IL-17A utilising a TLR-2 dependent mechanism [46] and
this may have contributed to the IL-17A signal detected by our
ELISA in both groups. An important role for the alveolar
macrophage in the early hours of pneumococcal infection has
Table 3. CFU recovered in BAL cell culture supernatant following OPKA.
IL-17A (ng/ml) Mean (95% confidence interval)
Ratio of IL-17A adjusted CFU/IL-17 adjusted CFU
at 12.5 ng/ml dose (95% confidence interval) [p]
Control IL-17A unadjusted IL-17A adjusted{
12.5 13.5 (8.8–18.2) 13.8 (7.2–20.4) 14.2 (10.7–17.6) —
125 16.8 (11.2–22.5) 13.7 (8.2–19.3) 10.5 (8.0–12.9) 0.739 (0.582–0.939) [p = 0.013]
625 16.8 (10.5–23.1) 12.4 (6.4–18.3) 8.9 (6.5–11.3) 0.629 (0.458–0.862) [p = 0.004]
{Adjusted for clustering within participants.
doi:10.1371/journal.ppat.1003274.t003
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been highlighted previously in murine models [48] and IL-17A
from innate sources are likely to be involved [49].
In this study we showed a significant increase in pneumococcal
killing by macrophages when exposed to 125 ng/ml of rhIL-17A,
a concentration that is in line with previous publications showing
an effect of IL-17 in this dose range [18,45,50–52]. This is also
consistent with the study by Lu et al. [18] who showed that human
neutrophils exposed to 100 ng/ml of rhIL-17A showed signifi-
cantly increased pneumococcal killing. Our data are also in line
with those of Higgins et al. [53] who showed that treatment of
murine peritoneal macrophages with 2.5–50 ng/ml of rmIL-17A
significantly enhanced killing of Bordetella pertussis. IL-17 also acts as
a recruitment and survival factor for monocytes and macrophages
[54], respectively, thus promoting macrophage-Th-17 interaction
in the small volume of airway lining fluid [55].
Both RA and RC subunits are required for human IL-17A
signalling with combined surface receptor density of RA and RC
determining the magnitude of the response [56] but we did not
find any positive correlations between our OPKA data and
receptor expression. In contrast to our hypothesis, we observed a
negative correlation between IL-17RC (but not RA) expression
and macrophage killing activity at the 125 ng/ml dose. The
modulation of killing by RC supports our observations of an IL-
17-dependent effect in our assay system rather than a contami-
nant. Furthermore the negative correlation between IL-17RC (but
not RA) expression and macrophage killing suggests that killing
may be mediated by a different IL-17RA heterodimer other than
RA:RC. RC may thus play a regulatory role in this process,
separate from its pro-inflammatory role within the RA:RC dimer,
fine tuning the phagocytic potential of alveolar macrophages and
thus susceptibility to infection. There is evidence that IL-17
receptors play regulatory roles during the inflammatory response
[30,52]. Recent observations have shown that RD expression
intensity can differentially regulate p38 mitogen-activated protein
kinase and nuclear factor-kappa B pathways and more importantly
the control of lung neutrophil recruitment in a CXCL2 dependent
manner [52]. Evidence provided here and elsewhere thus suggests
that the role of IL-17 receptors is more complex than initially
appreciated and may differ depending on the context. The role of
IL-17 receptors, other than the classical IL-17RA:RC heterodi-
mer, on alveolar macrophage function in health and disease
remains to be clarified and may determine the overall protective
effect of Th-17 cells.
Taken as a whole, these results have important implications for
vaccine design against pneumonia. First, they show that human
nasal carriage can boost innate (alveolar macrophage function)
and adaptive (TNF+IL-17A+ CD4+ memory T-cells) cellular lung
immunity that may protect the lung from pneumococcal challenge
and the establishment of infection in health, without significant
recruitment of neutrophils. When these and other protective
immunological mechanisms are compromised or the bacterial load
overwhelms innate defence mechanisms the responses described in
our study may synergise to enhance neutrophil mediated
recruitment into the airspace. Second, we have begun to define
the phenotypic and kinetic cellular responses elicited by pneumo-
coccal carriage – a natural immunising event, thus providing a
bench mark for vaccines that seek to protect against pneumonia.
Supporting Information
Figure S1 Flow Cytometry gating strategy to detect
cytokine positive CD4+ memory T cells in BAL. A BAL
Lymphocytes were identified on FSC and SSC analysis. B Gated
cells were measured for viability (Vivid negative) and CD3
expression. C Gated cells from B (viable CD3+ T-cells) were then
measured for CD3 and CD45RO expression to identify memory
(CD45RO+) CD3+ T-cells. D Viable CD3+ memory T cells were
gated onto a bivariate dot plot measuring CD3 and CD4 to
identify BAL CD4+ T-cells (black circle). CD4+ T-cell events from
E were gated onto a bivariate dot plot with CD3 expression on the
y-axis and either E and H TNF (AF488) or F and I IL-17A (PE) or
G and J IFNc (AF700) on the x-axis. Shown are CD4+ T-cell
responses when cultured in E, F and G media alone or following
stimulation with H, I and J influenza-antigen. Cytokine positive
events were identified as shown in E–J (boxed areas) and reported
as a percentage of total CD4+ memory T-cells for each condition.
(TIFF)
Figure S2 Pneumococcal-responding IL-17A+ and TNF+
CD4+ memory T-cells are present in blood from non-
colonised volunteers. A 6B pneumococcal culture supernatant
B heat-killed 6B pneumococci and C Influenza stimulated
PBMCs, from non-colonised volunteers (n = 8), analysed for
TNF, IL-17A and IFNc expression as a proportion of CD4+
memory T-cells. We detected a low frequency of TNF+ and IL-
17A+ CD4+ memory T-cells in response to pneumococcal
stimulation compared to vehicle control treated cells. * = p,0.05.
(TIFF)
Figure S3 Pneumococcal Carriage does not significantly
alter the influenza CD4+ T-cell response in BAL. BAL cells
from A non-colonised (n= 9) and B colonised volunteers (n = 11)
were stimulated with influenza. CD4+ memory T-cell expression
of TNF, IL-17A and/or IFNc, as indicated in legend, was
measured and recorded as a percentage. Responses shown are
background subtracted. In non-colonised volunteers BAL CD4 T
cell responses constitute mostly double (TNF/IFNc) and single
(TNF or IFNc) producing T cells. From pneumococcal colonised
volunteers, influenza specific responses are similar.
(TIFF)
Figure S4 BAL cells stimulated with pneumococci elicit
IL-2, IL-4, IL-6 IL-10, IL-22 but not IFNc. BAL cells from
non-colonised (open bars, n = 6) or colonised volunteers (closed
bars, n = 7) were left untreated (NS) or stimulated with
pneumococci (6B). Cell culture supernatants from non-colonised
and colonised volunteers were collected after 20 hours and
measured for the presence of IFNc, IL-2, IL-4, IL-6, IL-10 and
IL-22 in pg/ml as shown. * = p,0.05.
(TIFF)
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